NLC-Based Rifampicin Delivery System: Development and Characterization for Improved Drug Performance Against Staphylococcus aureus
Pharmaceutics · 19.06.2025 · 17 (6) · 799
DOI: 10.3390/pharmaceutics17060799 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 19.06.2025. Verfasst von Javiera Carrasco-Rojas und 6 weiteren Autor:innen. Beteiligte Einrichtung: Departamento de Ciencias y Tecnología Farmacéutica, Facultad de Ciencias Químicas y Farmacéuticas, Universidad de Chile, Santiago 8380494, Chile. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fondo Nacional de Desarrollo Científico y Tecnológico, FONDEF, Agencia Nacional de Investigación y Desarrollo.
Abstract (Originalsprache)
Background/Objectives: Rifampicin is a typical antibiotic used for the treatment of Staphylococcus aureus (S. aureus) infections; however, its clinical utility is limited by poor aqueous solubility, chemical instability, and increasing bacterial resistance. Nanostructured lipid carriers (NLCs) offer a promising strategy to improve drug solubility, stability, and antimicrobial performance.
Methods
In this study, rifampicin-loaded NLC (NLC-RIF) was developed using a hot homogenization with a low energy method and characterized in terms of particle size, polydispersity index, zeta potential, encapsulation efficiency, colloidal stability, and drug loading.
Results
In vitro release studies under sink conditions demonstrated a biphasic release pattern, best described by the Korsmeyer–Peppas model, suggesting a combination of diffusion and matrix erosion mechanisms. Antimicrobial activity against S. aureus revealed a substantial increase in potency for NLC-RIF, with an IC50 of 0.46 ng/mL, approximately threefold lower than that of free rifampicin. Cytotoxicity assays in HepG2 cells confirmed over 90% cell viability across all tested concentrations.
Conclusions
These findings highlight the potential of NLC-RIF as a biocompatible and effective nanocarrier system for enhancing rifampicin delivery and antibacterial activity.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Departamento de Ciencias y Tecnología Farmacéutica, Facultad de Ciencias Químicas y Farmacéuticas, Universidad de Chile, Santiago 8380494, Chile.
- Centro de Medicina Regenerativa, Facultad de Medicina, Clínica Alemana-Universidad del Desarrollo, Santiago 7550000, Chile.
- Escuela de Química y Farmacia, Facultad de Ciencias, Universidad San Sebastián, Campus Los Leones, Lota 2465, Providencia, Santiago 7510157, Chile.
- Centro Basal Ciencia & Vida, Fundación Ciencia & Vida, Av. del Valle Norte 725, Huechuraba 8580702, Chile.
- Centro de Nuevos Fármacos para Hipertensión e Insuficiencia Cardíaca, CENDHY, Santiago 8380494, Chile.
- Centro Avanzado de Enfermedades Crónicas, ACCDiS, Santiago 8380494, Chile.
ORCID-Profile: Javiera Carrasco-Rojas, Felipe I Sandoval, Christina M A P Schuh, Carlos F Lagos, Javier O Morales, Francisco Arriagada, Andrea C Ortiz
Förderung
- Fondo Nacional de Desarrollo Científico y Tecnológico
- FONDEF
- Agencia Nacional de Investigación y Desarrollo
- FONDAP
- FONDEQUIP
- FONDECYT Project
- Regular FONDECYT Project
- FONDEF Project
Zitieren
APA
Carrasco-Rojas, J., Sandoval, F. I., Schuh, C. M. A. P., Lagos, C. F., Morales, J. O., Arriagada, F., & Ortiz, A. C. (2025). NLC-Based Rifampicin Delivery System: Development and Characterization for Improved Drug Performance Against Staphylococcus aureus. Pharmaceutics, 17(6), 799. https://doi.org/10.3390/pharmaceutics17060799
Vancouver
Carrasco-Rojas J, Sandoval FI, Schuh CMAP, Lagos CF, Morales JO, Arriagada F, et al. NLC-Based Rifampicin Delivery System: Development and Characterization for Improved Drug Performance Against Staphylococcus aureus. Pharmaceutics. 2025;17(6):799. doi:10.3390/pharmaceutics17060799
BibTeX
@article{CarrascoRojas2025,
author = {Carrasco-Rojas, Javiera and Sandoval, Felipe I and Schuh, Christina M A P and Lagos, Carlos F and Morales, Javier O and Arriagada, Francisco and Ortiz, Andrea C},
title = {NLC-Based Rifampicin Delivery System: Development and Characterization for Improved Drug Performance Against Staphylococcus aureus},
journal = {Pharmaceutics},
year = {2025},
volume = {17},
number = {6},
pages = {799},
doi = {10.3390/pharmaceutics17060799}
}
EUVIMED